New data shows that local prostate radiotherapy improves OS in some men with newly diagnosed, metastatic prostate cancer

New data from the ongoing STAMPEDE trial in the UK and Switzerland has now confirmed that ablative radiation of the prostate itself (debulking of the primary tumor) improves overall survival (OS) in men newly diagnosed with metastatic prostate cancer who have a low metastatic disease burden but not in those with higher burden of disease. … READ MORE …

No survival benefit to debulking the prostate with radiation in first randomized clinical trial

The term “debulking” denotes the radical treatment (via prostatectomy or radiation therapy) of the cancerous prostate — lmost always in newly diagnosed patients — after distant metastases have been discovered. … READ MORE …

The genetics of prostate cancer risk among African males

A newly published study from a group of researchers at the Garvan Institute in Scotland has again confirmed the apparent genetic risk for some forms of prostate cancer among men of African ethnic origin. … READ MORE …

Does local treatment at time of diagnosis improve outcomes for men initially diagnosed with metastatic disease?

Over the years, a good deal of data has been accumulated suggesting that local treatment (ablation) of the primary tumor may have benefit in the long-term outcomes of men with metastatic prostate cancer at time of initial diagnosis. … READ MORE …

Initial local treatment and long-term survival of men with advanced prostate cancer

We have previously had no really accurate data on a very important question: Does local treatment of men initially diagnosed with advanced prostate cancer impact their long-term survival and mortality rates? … READ MORE …

Liquid biopsies, ctDNA, and the diagnosis and management of cancers

The American Society of Clinical Oncology (ASCO) and the College of Pathologists (CAP) have just issued a joint review of available information on clinical use of “liquid biopsies” to assess circulating levels of tumor DNA (ctDNA). … READ MORE …

CTC levels as a surrogate endpoint for clinical trials in mCRPC

A newly published analysis of data from five major clinical trials involving > 6,000 patients has provided us with additional information about circulating tumor cell (CTC) levels as an endpoint for clinical trials. … READ MORE …